It’s lonely out there sometimes

Have you often wondered about the challenges of going into the unknown with phase 1 or even phase 3 trials for cancer?

Sometimes it seems like the summer crowds packing Bournemouth beach and you can’t find any space or place to sit, while others are more akin to the lonely buoy marking an empty beach.

Today’s oncology target has seen both extremes in its time with breathless hype followed by the depths of despair and lost interest from many of the madding crowds.

It’s still going though, with phase 3 readouts awaited and new competitors still entering the landscape.

There’s also some emerging science, including biomarker data to explore…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by